Last reviewed · How we verify
Stopping dupilumab
Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation.
Dupilumab is a monoclonal antibody that targets the interleukin-4 receptor alpha subunit, which is involved in the signaling pathways of IL-4 and IL-13. It is primarily used for treating atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. The drug has shown significant efficacy in reducing symptoms and improving quality of life in these conditions. However, it is not approved by the FDA for use in stopping dupilumab, and its discontinuation should be managed carefully to avoid potential rebound effects or worsening of symptoms. Common side effects include injection site reactions, conjunctivitis, and upper respiratory tract infections.
At a glance
| Generic name | Stopping dupilumab |
|---|---|
| Sponsor | University Hospital, Toulouse |
| Drug class | Monoclonal antibody |
| Target | Interleukin-4 receptor alpha subunit (IL-4Rα) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting the IL-4 and IL-13 signaling pathways, dupilumab reduces the activation of immune cells and the production of inflammatory mediators, leading to a decrease in inflammation and associated symptoms.
Approved indications
Pipeline indications
Common side effects
- Injection site reactions
- Conjunctivitis
- Upper respiratory tract infections
Key clinical trials
- Withdrawal of Dupilumab in Severe Asthma (PHASE4)
- Evaluation of Patient Satisfaction During Treatment With Dupilumab in Severe and Recurrent Nasosinusal Polyposis Despite Appropriate Medical and Surgical Treatment.
Patents
| Patent | Expiry | Type |
|---|---|---|
| US8784804B2 | ||
| US9206250B2 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stopping dupilumab CI brief — competitive landscape report
- Stopping dupilumab updates RSS · CI watch RSS
- University Hospital, Toulouse portfolio CI